Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion

NCT ID: NCT02061813

Last Updated: 2021-07-26

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-01-31
• Study Completion Date: 2014-05-31

Brief Summary

The purpose of the study is to determine the irritation potential of repeat applications of abametapir lotion on normal skin.

Detailed Description

This will be a randomized, evaluator-blind, single-center, controlled, within-subject comparison study of the investigational products (abametapir lotion) and its vehicle lotion and positive and negative controls under occlusive conditions in healthy volunteers. All subjects will have the investigational product (abametapir lotion), the vehicle product, the positive control patch, and negative control patch applied to 4 randomly assigned, adjacent skin sites on the infrascapular area of their back, for the purpose of determining irritation potential.

The investigational products, vehicle, and controls will be applied to one side of the infrascapular area of the back. Evaluation of dermal reactions at the application sites will be assessed clinically using a visual scale that rates the degree of erythema, edema, and other signs of cutaneous irritation (see Section 3.5.5).

A total of 21 applications of each product will be made.

Conditions

Head Lice

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Abametapir lotion 0.74% w/w

Applied 0.2 mL topically under occlusive condition

Group Type: EXPERIMENTAL

Abametapir Lotion 0.74% w/w

Intervention Type: DRUG

applied 0.2 mL topically under occlusive condition

Vehicle lotion

Applied 0.2 mL topically under occlusive condition

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Sodium Lauryl Sulfate

Positive control applied 0.2 mL topically under occlusive condition

Group Type: OTHER

Sodium Lauryl Sulfate

Intervention Type: DRUG

Sodium Lauryl Sulfate is prepared as a 0.2% aqueous solution by the site for topical administration, and applied 21 times over consecutive days under occlusive conditions, will serve as a positive control.

Saline 0.9%

Negative control applied 0.2 mL topically under occlusive condition

Group Type: OTHER

Saline 0.9%

Intervention Type: DRUG

A solution of 0.9% saline for topical administration, applied 21 times over consecutive days under occlusive conditions, will serve as a negative control

Interventions

Abametapir Lotion 0.74% w/w

applied 0.2 mL topically under occlusive condition

Intervention Type: DRUG

Sodium Lauryl Sulfate

Sodium Lauryl Sulfate is prepared as a 0.2% aqueous solution by the site for topical administration, and applied 21 times over consecutive days under occlusive conditions, will serve as a positive control.

Intervention Type: DRUG

Saline 0.9%

A solution of 0.9% saline for topical administration, applied 21 times over consecutive days under occlusive conditions, will serve as a negative control

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Are healthy (to be confirmed by medical history) males or females, 18 years of age or older;

2. In the case of females of childbearing potential, are using an acceptable form of birth control (oral/implant/injectable/transdermal contraceptives, intrauterine device, condom with spermicide, diaphragm with spermicide, abstinence, partner's vasectomy). Abstinence or vasectomized partner are acceptable if the female subject agrees to implement one of the other acceptable methods of birth control if her lifestyle/partner changes;

3. If female of childbearing potential, have a negative urine pregnancy test (UPT) at Day 1, and are willing to submit to a pregnancy test at the end of study (EOS);

4. Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events;

5. Are of any skin type or race, providing the skin pigmentation will allow discernment of erythema;

6. Complete a patch study Medical Screening form as well as a Medical Personal History form; and

7. Read, understand, and provide signed informed consent.

Exclusion Criteria

1. Have any visible skin disease at the application site which, in the opinion of the investigative personnel, will interfere with the evaluation of the test site reaction;

2. Are not willing to refrain from using topical/systemic analgesics such as aspirin (daily use of 81 mg aspirin is acceptable), Aleve, Motrin, Advil, or Nuprin for 72 hours prior to and during the study (occasional use of acetaminophen will be permitted);

3. Are using inhaled/systemic/topical corticosteroids in the 3 weeks prior to and during the study, or systemic/topical antihistamines for 72 hours prior to and during the study;

4. Are using medication which, in the opinion of the investigative personnel, will interfere with the study results, including anti-inflammatory medications;

5. Are unwilling or unable to refrain from the use of sunscreens, cosmetics, creams, ointments, lotions, or similar products on the back during the study;

6. Have psoriasis and/or active atopic dermatitis/eczema;

7. Are females who are pregnant, plan to become pregnant during the study, or are breast-feeding a child;

8. Have a known sensitivity to constituents present in the material being evaluated;

9. Have damaged skin in or around the test sites, including sunburn, excessively deep tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or other disfigurations of the test site

10. Have received treatment for any type of internal cancer within 5 years prior to study entry;

11. Have a history of, or are currently being treated for skin cancer;

12. Are currently participating in any other clinical trial,

13. Have any known sensitivity to adhesives; and/or

14. Have received any investigational treatment(s) within 4 weeks prior to study entry.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Dr. Reddy's Laboratories Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jonathan Dosik

Role: PRINCIPAL_INVESTIGATOR

TKL Research, Inc.

Locations

TKL Reserach Inc

Paramus, New Jersey, United States

Countries

United States

Other Identifiers

Ha03-007

Identifier Type: -

Identifier Source: org_study_id